PRQR Stock — ProQR Therapeutics N.V.: Cash, EV, Pipeline

Share price

$1.83

Market cap

$258.3M

Cash

$164.4M

Enterprise value

$99.5M

Balance sheet

Cash	$164.4M
Debt	$5.6M
Net cash	$158.8M
Enterprise value	$99.5M
Basic shares	141.5M shares
Fully diluted shares	139.8M shares
Fully diluted market cap	$255.7M
Cash per share	$1.16

Cash figures as of 2026-07-15. Database snapshot: 2026-09-21.

Price history

Loading PRQR daily closes…

Loading price history…

Pipeline assets

AX-0810

Phase 1 · Active Modality: RNA editing (Axiomer platform)

Target NTCP (na-taurocholate cotransporting polypeptide)

Indications

Cholestatic diseases (Phase 1)

Status note Lead Axiomer RNA editing product candidate targeting NTCP. Phase 1 clinical development started in December 2025.

Per-asset detail extracted from the 20-F filed 2026-03-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	sepofarsen
Lead indication	Leber Congenital Amaurosis 10
Lead phase	Phase 2/3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03913143	Phase 2/3	Active, not recruiting	Sponsor	ProQR Therapeutics	—	Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis	—
NCT04123626	Phase 1/2	Active, not recruiting	Sponsor	ProQR Therapeutics	—	Autosomal Dominant Retinitis Pigmentosa; Eye Diseases; Eye Diseases, Hereditary	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for ProQR Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PRQR — ProQR Therapeutics N.V.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials